• Company
• New myelodysplastic syndrome drug 'Reblozyl' lands Big 5 DC
• by Eo, Yun-Ho Sep 30, 2024 05:46am

• Policy
• Stelara biosimilar Steqeyma IV approved for use in Korea
• by Lee, Hye-Kyung Sep 30, 2024 05:46am

• Company
• Phesgo can be prescribed in Korea with reimbursement
• by Eo, Yun-Ho Sep 30, 2024 05:46am

• Company
• K-Phama companies are targeting Southeast Asia
• by Heo, sung-kyu Sep 27, 2024 05:53am

• Company
• 'Treatment options for psoriasis are evolving'
• by Son, Hyung Min Sep 27, 2024 05:53am

• Company
• KRPIA expresses concerns over drug approval fee hike
• by Eo, Yun-Ho Sep 27, 2024 05:53am

• Policy
• COVID-19 drugs to be reimbursable, "KRW 50,000 co-payment"
• by Lee, Jeong-Hwan Sep 27, 2024 05:53am

• Company
• Switching between JAKis for RA yet to be reimbursed
• by Eo, Yun-Ho Sep 27, 2024 05:52am

• Policy
• 2nd Approval-Evaluation-Negotiation pilot project imminent
• by Kim, Jin-Gu Sep 26, 2024 05:51am

• Company
• Minjung Jung to head Corporate Affairs at Sanofi KR, NZ, AU
• by Eo, Yun-Ho Sep 26, 2024 05:51am